drugset / Trial / NCT04838548
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to assess the efficacy, safety of MRG003 as single agent in EGFR-positive advanced non-small cell lung cancer
Timeline
- Start
- 2021-04-16
- Primary completion
- 2023-03-27
- Completion
- 2023-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Becotatug Vedotin | Other / unclassified | 2 mg/kg | Intravenous |